FDA drug regulation workshop
FDA will hold a two-day public meeting June 8-9 to provide information about drug and device regulation to the regulated industry. Called "Drugs and Devices - Promoting and Protecting the Public Health Through Risk Management and Product Cycle Improvement," the workshop will address: a risk management approach to consumer protection and industry regulation; how quality management systems (including corrective and preventive action) contribute to product cycle improvement; supplier management and component controls for drugs and devices; adverse drug event reporting requirements; medical device reporting requirements; recalls, corrections and removals; and complaint handling from the FDA investigator's perspective
You may also be interested in...
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.